This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Immunomedics Reports Results With IMMU-132 In Patients With Pancreatic Cancer

NEW ORLEANS, May 20, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported a stabilization of disease, as measured by computed tomography (CT) according to RECIST criteria, in pancreatic cancer patients with advanced disease and who failed 1-5 prior therapies. In a group of 13 CT-assessable patients receiving repeated doses of the Company's investigational antibody-drug conjugate (ADC), IMMU-132, a median time-to-progression of 12.7 weeks was reported (range 4.3-21.4 weeks), which is better than the median 8.0 weeks (range 4-36 weeks) estimated from their last prior therapy.

Results from the ongoing Phase I/II study were presented at the American Association for Cancer Research Special Conference on Pancreatic Cancer: Innovations in Research and Treatment by Vincent J. Picozzi Jr., M.D., Director of the Pancreas Center of Excellence at the Virginia Mason Medical Center's Digestive Disease Institute, Seattle, WA.

It is known that in such advanced, highly malignant cancers, responses and outcome are poorer with each successive treatment. "This is why we are encouraged that this group of heavily pretreated, advanced pancreatic cancer patients showed a longer period of disease control compared with their most recent therapy before entering this trial," Dr. Picozzi stated.

A total of 15 advanced PDC patients who relapsed after a median of 2 prior therapies (range 1-5) have been enrolled in the multicenter trial. One patient was not evaluated due to clinical progression, while another patient's CT assessment is pending. Patients were administered IMMU-132 on days 1 and 8 in repeated 21-day cycles for up to 8 cycles. IMMU-132 consists of the Company's proprietary anti-TROP-2 humanized antibody conjugated with a high number of SN-38 drug molecules by a site-specific linker technology. Preclinical studies have indicated that a significantly higher amount of SN-38, the active metabolite of irinotecan, is delivered to human cancers growing in mice than when high doses of the parent compound, irinotecan, is given.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs